Systematic review and quality analysis of emerging diagnostic measures for calcium pyrophosphate crystal deposition disease.

ObjectivesCalcium pyrophosphate crystal deposition disease (CPPD) is common, yet prevalence and overall clinical impact remain unclear. Sensitivity and specificity of CPPD reference standards (conventional crystal analysis (CCA) and radiography (CR)) were meta-analysed by EULAR (published 2011). Since then, new diagnostic modalities are emerging. Hence, we updated 2009-2016 literature findings by systematic review and evidence grading, and assessed unmet needs.MethodsWe performed systematic search of full papers (PubMed, Scopus/EMBASE, Cochrane 2009-2016 databases). Search terms included CPPD, chondrocalcinosis, pseudogout, ultrasound, MRI, dual energy CT (DECT). Paper selection, data abstraction, EULAR evidence level, and Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 bias and applicability grading were performed independently by 3 authors.ResultsWe included 26 of 111 eligible papers, which showed emergence in CPPD diagnosis of ultrasound (U/S), and to lesser degree, DECT and Raman spectroscopy. U/S detected CPPD crystals in peripheral joints with sensitivity >80%, superior to CR. However, most study designs, though analytical, yielded low EULAR evidence level. DECT was marginally explored for CPPD, compared with 35 published DECT studies in gout. QUADAS-2 grading indicated strong applicability of U/S, DECT and Raman spectroscopy, but high study bias risk (in ∼30% of papers) due to non-controlled designs, and non-randomised subject selection.ConclusionsThough CCA and CR remain reference standards for CPPD diagnosis, U/S, DECT and Raman spectroscopy are emerging U/S sensitivity appears to be superior to CR. We identified major unmet needs, including for randomised, blinded, controlled studies of CPPD diagnostic performance and rigorous analyses of 4 T MRI and other emerging modalities

Renormalization Group Method and Reductive Perturbation Method

It is shown that the renormalization group method does not necessarily eliminate all secular terms in perturbation series to partial differential equations and a functional subspace of renormalizable secular solutions corresponds to a choice of scales of independent variables in the reductive perturbation method.Comment: 5 pages, late

Maximal power output of a stochastic thermodynamic engine

Classical thermodynamics aimed to quantify the efficiency of thermodynamic engines, by bounding the maximal amount of mechanical energy produced, compared to the amount of heat required. While this was accomplished early on, by Carnot and Clausius, the more practical problem to quantify limits of power that can be delivered, remained elusive due to the fact that quasistatic processes require infinitely slow cycling, resulting in a vanishing power output. Recent insights, drawn from stochastic models, appear to bridge the gap between theory and practice in that they lead to physically meaningful expressions for the dissipation cost in operating a thermodynamic engine over a finite time window. Indeed, the problem to optimize power can be expressed as a stochastic control problem. Building on this framework of stochastic thermodynamics we derive bounds on the maximal power that can be drawn by cycling an overdamped ensemble of particles via a time-varying potential while alternating contact with heat baths of different temperature (Tc cold, and Th hot). Specifically, assuming a suitable bound M on the spatial gradient of the controlling potential, we show that the maximal achievable power is bounded by [Formula presented]. Moreover, we show that this bound can be reached to within a factor of [Formula presented] by operating the cyclic thermodynamic process with a quadratic potential

Lasant Materials for Blackbody-Pumped Lasers

Blackbody-pumped solar lasers are proposed to convert sunlight into laser power to provide future space power and propulsion needs. There are two classes of blackbody-pumped lasers. The direct cavity-pumped system in which the lasant molecule is vibrationally excited by the absorption of blackbody radiation and laser, all within the blackbody cavity. The other system is the transfer blackbody-pumped laser in which an absorbing molecule is first excited within the blackbody cavity, then transferred into a laser cavity when an appropriate lasant molecule is mixed. Collisional transfer of vibrational excitation from the absorbing to the lasing molecule results in laser emission. A workshop was held at NASA Langley Research Center to investigate new lasant materials for both of these blackbody systems. Emphasis was placed on the physics of molecular systems which would be appropriate for blackbody-pumped lasers

Adaptation of multidimensional group particle tracking and particle wall-boundary condition model to the FDNS code

A particulate two-phase flow CFD model was developed based on the FDNS code which is a pressure based predictor plus multi-corrector Navier-Stokes flow solver. Turbulence models with compressibility correction and the wall function models were employed as submodels. A finite-rate chemistry model was used for reacting flow simulation. For particulate two-phase flow simulations, a Eulerian-Lagrangian solution method using an efficient implicit particle trajectory integration scheme was developed in this study. Effects of particle-gas reaction and particle size change to agglomeration or fragmentation were not considered in this investigation. At the onset of the present study, a two-dimensional version of FDNS which had been modified to treat Lagrangian tracking of particles (FDNS-2DEL) had already been written and was operational. The FDNS-2DEL code was too slow for practical use, mainly because it had not been written in a form amenable to vectorization on the Cray, nor was the full three-dimensional form of FDNS utilized. The specific objective of this study was to reorder to calculations into long single arrays for automatic vectorization on the Cray and to implement the full three-dimensional version of FDNS to produce the FDNS-3DEL code. Since the FDNS-2DEL code was slow, a very limited number of test cases had been run with it. This study was also intended to increase the number of cases simulated to verify and improve, as necessary, the particle tracking methodology coded in FDNS

The preparation, characterization, and pharmacokinetic studies of chitosan nanoparticles loaded with paclitaxel/dimethyl-β-cyclodextrin inclusion complexes.

A novel biocompatible and biodegradable drug-delivery nanoparticle (NP) has been developed to minimize the severe side effects of the poorly water-soluble anticancer drug paclitaxel (PTX) for clinical use. PTX was loaded into the hydrophobic cavity of a hydrophilic cyclodextrin derivative, heptakis (2,6-di-O-methyl)-β-cyclodextrin (DM-β-CD), using an aqueous solution-stirring method followed by lyophilization. The resulting PTX/DM-β-CD inclusion complex dramatically enhanced the solubility of PTX in water and was directly incorporated into chitosan (CS) to form NPs (with a size of 323.9–407.8 nm in diameter) using an ionic gelation method. The formed NPs had a zeta potential of +15.9–23.3 mV and showed high colloidal stability. With the same weight ratio of PTX to CS of 0.7, the loading efficiency of the PTX/DM-β-CD inclusion complex-loaded CS NPs was 30.3-fold higher than that of the PTX-loaded CS NPs. Moreover, it is notable that PTX was released from the DM-β-CD/CS NPs in a sustained-release manner. The pharmacokinetic studies revealed that, compared with reference formulation (Taxol(®)), the PTX/DM-β-CD inclusion complex-loaded CS NPs exhibited a significant increase in AUC(0→24h) (the area under the plasma drug concentration–time curve over the period of 24 hours) and mean residence time by 2.7-fold and 1.4-fold, respectively. Therefore, the novel drug/DM-β-CD inclusion complex-loaded CS NPs have promising applications for the significantly improved delivery and controlled release of the poorly water-soluble drug PTX or its derivatives, thus possibly leading to enhanced therapeutic efficacy and less severe side effects